SCHEMBL21640652

SCHEMBL21640652

CC(C)(C)OC(=O)N1CC(NC(=O)Nc2ccccn2)C1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 3/20 0.50
DRD2 P14416 1/20 0.49
DRD4 P21917 1/20 0.49
DRD3 P35462 1/20 0.49
GPR119 Q8TDV5 2/20 0.47
ADORA2A P29274 2/20 0.47
ADORA2B P29275 2/20 0.47
NOS2 P35228 1/20 0.44
POLR1A O95602 1/20 0.43
NPC1 O15118 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
PIM1 P11309 1/20 0.43
ADORA1 P30542 1/20 0.43
FLT3 P36888 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PIM3 Q86V86 1/20 0.43
AURKB Q96GD4 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30585858 0.87 NOS2 (0.54) USP30GPR119ADORA2AADORA2BNOS2
SCHEMBL18497654 0.87 NOS2 (0.54) USP30GPR119ADORA2AADORA2BNOS2
SCHEMBL4911832 0.84 LMNA (0.51) USP30GPR119NPC1RAB9AGAA
SCHEMBL34473639 0.80 NOS2 (0.62) USP30GPR119ADORA2AADORA2BNOS2
SCHEMBL28463063 0.79 PTPN2 (0.62) USP30GPR119NOS2NPC1RAB9A
SCHEMBL21598943 0.78 USP30 (0.55) USP30GPR119NOS2
SCHEMBL21640139 0.78 USP30 (0.60) USP30GPR119ADORA2AADORA2BPOLR1A
SCHEMBL1087667 0.77 NOS2 (0.72) USP30GPR119NOS2NPC1RAB9A
SCHEMBL13216309 0.77 GPR119 (0.47) USP30GPR119NOS2GAA
SCHEMBL3568047 0.76 PHGDH (0.54) GPR119NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3604305-B1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF WAKUNAGA PHARMA CO LTD (JP) 2024-08-28 EP disclosed
CN-110520422-B Novel pyridonecarboxylic acid derivative or salt thereof 涌永制药株式会社 2023-09-05 CN disclosed
US-11286255-B2 Pyridone carboxylic acid derivative or salt thereof WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2022-03-29 US disclosed
US-20200062752-A1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2020-02-27 US disclosed
EP-3604305-A1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF Wakunaga Pharmaceutical Co., Ltd. (JP) 2020-02-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062752-A1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF RAB10, HDAC10, NEK10 USP30 1007/4885DRD2 1505/4885DRD4 1655/4885
US-11286255-B2 Pyridone carboxylic acid derivative or salt thereof RARA, RAB10, RABL6 USP30 1458/4885DRD2 1824/4885DRD4 1998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.